Moreover, compared with placebo, colchicine use was associated with reduced clonal growth in TET2-driven CH (βtime on colchicine: 0.09 [95% CI: −0.04 to 0.22] vs. βtime placebo: 0.27 [95% CI: 0.16 to 0.37]; p for interaction = 0.04). Here, TET2 is linked to cyclic hematopoiesis.